Generic-And-Innovative-Drugs-Market-In-Central-Europe-2012-Comparative-Analysis.png

Single User License - Generic and Innovative Drugs Market in Central Europe

$3,500.00
April 2012
303
Also Available:

For the makers of generic and innovative drugs, Central Europe’s six countries represent a valuable market.

The market, however, is being redrawn by legislative and regulatory actions that change everything from reimbursement policy (and margins), to drug patent expiry and data exclusivity periods. Add in challenges from counterfeit drugs and new patient and physician mindsets, and “business as usual” can put even established players at risk.

Here is how to understand this new market environment — and spot where your own best opportunities exist.

Here is your complete guide to how new laws, regulations and physician and patient attitudes are reshaping Central Europe’s market for generic and innovative drugs.

Market values, medicines and more. This one clearly written report explains exactly how legislative developments occurring in all six Central European countries will affect market value, regulatory framework, sales of specific products, and the fortunes of key generics and innovative drug companies between now and 2014. 

Buy now for the insider facts, analysis and forecasts to profit  in Central Europe’s changing markets for generic and innovative drugs, including:

  • Market value and market share: From now through 2014, the value of Central Europe’s generics drug market and innovative drug market and market share analysis, plus country-by-country market share and market value forecasts.
  • Reimbursement and pricing changes: Summary of each country’s reimbursement system, VAT rate, reimbursement levels, regulations affecting prices of non-reimbursed and reimbursed medicines, markups for medicines — including averages and official figures, and most-recent (and expected) changes to reimbursement lists.
  • Patent issues: Drug patent expiry and data exclusivity periods.
  • Patient and doctor attitudes: Viewpoints of Central European patients and physicians, including their opinions toward or against use of generic and innovative drugs.
  • Top-selling products: Profiles of the top-selling medicines in each category, with prices and industry markups.
  • The impact of counterfeit medicines: The size of the market share they occupy and each country’s policies for regulating the manufacture, distribution and sale to address counterfeiting.
  • Corporate profiles: Information on the largest generic and innovative drug producers — in each country and across the region as a whole.

Buy now for the current, unbiased information you need to identify which Central European countries have the greatest potential for international generic and innovative drug makers — and which countries are legal and regulatory mine fields.

Generic and Innovative Drugs Market in Central Europe 2012: Comparative Analysis, Reimbursement Policies and Development Forecasts for 2012-2014 is offered by FDAnews in a 303-page PDF format:  $3,500 for single user; $5,250 for 5-user license. Site and global licenses available. Contact Customer Service for a quote or more information.